Latest Patent Protection News

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

EcoGraf Limited has been granted its first Australian patent for its innovative HFfree® purification technology, reinforcing its position in the battery anode materials market. This milestone follows a recent breakthrough that cut purification costs by 25%, boosting the commercial potential of its purification facilities.

EcoGraf Limited reveals a major breakthrough in its HFfree® graphite purification technology, cutting operating costs by 25% and projecting a US$282 million NPV for its initial 25,000 tonnes per annum facility. This positions the company as a competitive, eco-friendly supplier amid rising global demand and geopolitical shifts in battery materials.

Hazer Group has filed patents for a breakthrough graphite purification process that could unlock access to the lucrative battery materials market amid tightening global supply. This innovation positions Hazer to meet surging demand for high-purity graphite essential for lithium-ion batteries.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.

Element 25 Limited has locked in AU$50 million in senior debt from the Northern Australia Infrastructure Facility to expand its Butcherbird manganese project, while advancing its US battery-grade manganese refinery with significant government grants and patent protections.

Nanoveu Limited has accelerated its commercial and technological momentum with a $3.02 million capital raise, a breakthrough 33% increase in drone flight time using its edge-AI chip, and progress toward a U.S. OTCQB listing.

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.